Validation of the method for studies of glucokinase activators by the spectrophotometric method in an in vitro test system is carried out. The advantage of NAD coenzyme vs. thio-NAD is proven. Manifest activation of glucokinase by MBX-2982 compound (GPR119 agonist) in a wide range of concentrations is demonstrated experimentally.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
GOST R ISO 5725-1-2002. Accuracy (Correctness and Precision) of Methods and Results of Measurement. Moscow, 2009. Russian.
Desai UJ, Slosberg ED, Boettcher BR, Caplan SL, Fanelli B, Stephan Z, Gunther VJ, Kaleko M, Connelly S. Phenotypic correction of diabetic mice by adenovirus-mediated glucokinase expression. Diabetes. 2001;50(10):2287-2295.
Eiki J, Nagata Y, Futamura M, Sasaki-Yamamoto K, Iino T, Nishimura T, Chiba M, Ohyama S, Yoshida-Yoshimioto R, Fujii K, Hosaka H, Goto-Shimazaki H, Kadotani A, Ohe T, Lin S, Langdon RB, Berger JP. Pharmacokinetic and pharmacodynamic properties of the glucokinase activator MK-0941 in rodent models of type 2 diabetes and healthy dogs. Mol. Pharmacol. 2011;80(6):1156-1165.
Ishikawa M, Nonoshita K, Ogino Y, Nagae Y, Tsukahara D, Hosaka H, Maruki H, Ohyama S, Yoshimoto R, Sasaki K, Nagata Y, Eiki J, Nishimura T. Discovery of novel 2-(pyridine-2-yl)-1H-benzimidazole derivatives as potent glucokinase activators. Bioorg. Med. Chem. Lett. 2009;19(15):4450-4454.
Jain S, Gupta N, Jindal R, Dubey T, Agarwal N, Siddiqui A, Wangnoo SK. Newer anti-hyperglycemic agents in type 2 diabetes mellitus — Expanding the horizon. Apollo Medicine. 2013;10(2):108-112. doi.org/https://doi.org/10.1016/j.apme.2013.05.013.
Kamata K, Mitsuya M, Nishimura T, Eiki J, Nagata Y. Structural basis for allosteric regulation of the monomeric allosteric enzymehuman glucokinase. Structure. 2004;12(3):429-438.
Leighton B, Atkinson A, Coghlan MP. Small molecule glucokinase activators as novel anti-diabetic agents. Biochem. Soc. Trans. 2005;33(Pt. 2):371-374.
Matschinsky FM. Assessing the potential of glucokinase activators in diabetes therapy. Nat. Rev. Drug Discov. 2009;8(5):399-416.
Qian-Cutrone J, Ueki T, Huang S, Mookhtiar KA, Ezekiel R, Kalinowski SS, Brown KS, Golik J, Lowe S, Pirnik DM, Hugill R, Veitch JA, Klohr SE, Whitney JL, Manly SP. Glucolipsin A and B, two new glucokinase activators produced by Streptomyces purpurogeniscleroticus and Nocardia vaccinii. J. Antibiot. (Tokyo). 1999;52(3):245-255.
Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J. Comput. Chem. 2010;31(2):455-461.
Waring MJ, Bennett S, Boyd S, Campbell L, Davies R, Hargreaves D, MacFaul P, Martin NG, Ogg DJ, Robb GR, Wilkinson G, Wood JM. Optimising pharmacokinetics of glucokinase activators with matched triplicate design sets — the discovery of AZD3651 and AZD9485. Med. Chem. Comm. 2013;4(4):663-668.
Waring MJ, Clarke DS, Fenwick MD, Godfrey L, Groombridge SD, Johnstone C, McKerrecher D, Pike KG, Rayner JW, Robb GR, Wilson I. Property based optimisation of glucokinase activators-discovery of the phase IIb clinical candidate AZD1656. Med.Chem. Comm. 2012;3(9):1077-1081
Author information
Authors and Affiliations
Corresponding author
Additional information
Translated from Byulleten’ Eksperimental’noi Biologii i Meditsiny, Vol. 163, No. 5, pp. 657-660, May, 2017
Rights and permissions
About this article
Cite this article
Spasov, A.A., Kosolapov, V.A., Babkov, D.A. et al. Effect of GRP119 Receptor Agonist, Compound MBX-2982, on Activity of Human Glucokinase. Bull Exp Biol Med 163, 695–698 (2017). https://doi.org/10.1007/s10517-017-3881-0
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10517-017-3881-0